Merck recalling VAQTA hepatitis A vaccine
Merck recalling VAQTA hepatitis A vaccine
Merck & Co., Inc. is voluntarily recalling specified lots of VAQTA (hepatitis A vaccine, inactivated) in prefilled syringes. Re-tests of VAQTA have revealed a decreased antigen content in some syringes below the established minimum specification. As a result, a possibility exists that persons vaccinated with VAQTA in prefilled syringes from the indicated lots may be insufficiently protected against hepatitis A.
Patients who may have received doses from the indicated lots would have been vaccinated after May 29, 2001, with the adult formulation (50 U/1 mL), and after Aug. 9, 1999, with the pediatric/adolescent formulation (25 U/0.5 mL). Guidelines for antibody testing and revaccination of these patients are available. See the "Dear Healthcare Professional" letter for more details located on the web: www.fda.gov/medwatch/SAFETY/2001/safety01.htm#vaqta.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.